IOL Chemicals and Pharmaceuticals share news, announcements and annual reports
NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap
IOL Chemicals and Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1991 on BSE, Nov 2010 on NSE
Last close ₹177.65down ₹7.28 (3.94%)BSE ₹177.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹184.93.
30 Oct: open ₹186.40, high ₹186.40, low ₹176.02
52-week range of traded prices to 30 Oct 2026
₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,215 Cr1,024th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.66
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.71
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.56%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 18,08,91234.0% delivered
IOL Chemicals and Pharmaceuticals share news and announcements
709 announcements, routine notices left out, newest first. Page 15 of 15.
Apr 2011
15 Apr · Results
Company shall submit Audited Financial Results for the year ended March 31, 2011 with the stock exchanges on or before May 30, 2011.
Feb 2011
2 Feb · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on February 07, 2011 inter-alia to consider the un-audited financial results of the Company for the quarter / nine months ended December 31, 2010. The Company has now informed the Exchange that the meeting of Board of Directors convened on February 07, 2011 has been postponed to February 08, 2011 inter-alia to consider the un-audited financial results of the Company for the quarter / nine months ended December 31, 2010.
Jan 2011
28 Jan · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter / nine months ended December 31, 2010.
Dec 2010
Nov 2010
9 Nov · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter / half year ended September 30, 2010.9 Nov · Updates
Company has obtained a Certificate of Suitability for its manufacturing facilities for Ibuprofen from European Directorate for the Quality of Medicines and HealthCare. CEPs are recognised by the signatory parties of the Convention on the Elaboration of a European Pharmacopoeia, i.e. all member states and the European union.